Products Cited in Publications Worldwide NR4A1 deficiency promotes carotid plaque vulnerability by activating integrated stress response via targeting Bcat1

NR4A1 deficiency promotes carotid plaque vulnerability by activating integrated stress response via targeting Bcat1

Chen, Long; Shi, Yiping; Xiao, Danrui; Huang, Yijie; Jiang, Yangjing; Liang, Min; Liang, Feng; Xue, Jieyuan; Chen, Haiping; Liu, Zhitong

DOI: PMID:

Abstract

Rupture of vulnerable carotid atherosclerotic plaque is one of the leading causes of ischemic stroke. However, the mechanisms driving the transition from stable to vulnerable plaques have not yet been elucidated. NR4A1 is an orphan nuclear receptor that functions in various inflammatory diseases. To explore the role of NR4A1 in vulnerable plaque formation, we generated a vulnerable plaque mouse model by combining partial ligation of the left common carotid artery and left renal artery in ApoE−/− and ApoE−/−;NR4A1−/− mice. Our research revealed that NR4A1 deficiency significantly worsened the pathology of vulnerable plaque, increasing intraplaque hemorrhage, rupture with thrombus, and the occurrence of multilayer with discontinuity. Moreover, NR4A1 deficiency exacerbated macrophage infiltration, inflammation, and oxidative stress. Mechanistically, we identified Bcat1 as the target of NR4A1. NR4A1 modulated the integrated stress response (ISR) in macrophages by transcriptionally inhibiting Bcat1, thus influencing the progression of vulnerable plaque. ISR inhibitor GSK2606414 or Bcat1 inhibitor ERG240 significantly ameliorated atherosclerotic plaque formation and increased plaque stability. Notably, supplementation with Celastrol, an herbal extract, stabilized atherosclerotic plaques in mice. These findings suggest that NR4A1 deficiency exacerbates vulnerable plaque by activating ISR via targeting Bcat1. The NR4A1/Bcat1/ISR axis is therefore an important therapeutic target for stabilizing atherosclerotic plaque.

Keywords

NR4A1 ; Integrated stress response ; Vulnerable plaque ; Bcat1

Purchased from AmBeed

GSK2606414

A1544251337531-36-898%

GSK2606414

146.0/50mg

Detail